Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA in mCRPC
NCT04033432Phase 2Unknown
- Sponsor
- Northwestern University
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sephb4-hsa in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Northwestern University. Status: unknown.
02
Drugs
sephb4-hsa
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04033432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033432.